uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

A class action lawsuit was filed against uniQure ($QURE) on February 10, 2026. Plaintiffs -investors- in the federal securities class action allege...

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims

Barclays analyst Eliana Merle maintained a Hold rating on uniQure on March 20 and set a price target of $25.00. The company’s shares closed last Fr...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	QURE	$15.89	0.00%	1.45M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	QURE	$15.89	0%	1.45M
3
4
5
6

QURE

QURE

No Data Available

Get QURE Data in Excel

Get QURE Data in Excel